Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies OLS miRNA effect size OLS covariates effect size
1 hsa-miR-107 WIF1 0.35 0.52382 2.05 3.0E-5 miRanda -0.81 1.0E-5 NA -0.81 type:-3.39, stage:-0.37, histology:-0.15, PAM50:-0.45, ER:0.11, PR:0.07, HER2:-0.17, Triple_Negative:1.68
2 hsa-miR-484 SFRP1 0.41 0.45389 3.81 0 MirTarget -0.74 0 NA -0.79 type:-5.75, stage:-0.19, histology:-0.12, PAM50:-1.1, ER:0.39, PR:-0.38, HER2:-1.15, Triple_Negative:1.64
3 hsa-miR-1301-3p SFRP1 1.13 0.00036 3.81 0 MirTarget -0.63 0 NA -0.54 type:-5.36, stage:-0.13, histology:-0.13, PAM50:-1.1, ER:0.15, PR:-0.44, HER2:-0.96, Triple_Negative:1.68
4 hsa-miR-16-5p WNT5A 0.61 0.44106 -0.49 0.23864 miRNAWalker2 validate -0.44 0 NA -0.48 type:2.47, stage:-0.21, histology:-0.1, PAM50:-0.03, ER:-0.02, PR:0.72, HER2:0.36, Triple_Negative:0.35
5 hsa-miR-107 FZD10 0.35 0.52382 -0.3 0.16314 miRanda -0.4 0 NA -0.45 type:0.61, stage:-0.18, histology:0.07, PAM50:-0.05, ER:0.42, PR:-0.11, HER2:-0.2, Triple_Negative:0.04
6 hsa-miR-590-3p WIF1 1.01 0 2.05 3.0E-5 PITA; miRanda; mirMAP -0.64 0 NA -0.44 type:-3.84, stage:-0.32, histology:-0.14, PAM50:-0.54, ER:-0.07, PR:0.06, HER2:-0.11, Triple_Negative:1.5
7 hsa-miR-24-3p CAMK2B 0.83 0.36962 -1.56 0 MirTarget -0.67 0 NA -0.42 type:3.05, stage:0.05, histology:0.05, PAM50:0.45, ER:0.64, PR:0.38, HER2:-0.14, Triple_Negative:0.63
8 hsa-miR-30e-5p WNT5A 0.74 0.51197 -0.49 0.23864 mirMAP -0.36 0 NA -0.41 type:2.04, stage:-0.22, histology:-0.12, PAM50:-0.11, ER:0.07, PR:0.74, HER2:0.34, Triple_Negative:0.28
9 hsa-miR-17-3p FZD4 1.47 0.04186 -0.76 0.18617 MirTarget -0.49 0 NA -0.37 type:-3.88, stage:-0.05, histology:-0.03, PAM50:-0.05, ER:-0.26, PR:-0.11, HER2:0.08, Triple_Negative:-0.65
10 hsa-miR-200c-3p FZD4 0.37 0.75644 -0.76 0.18617 mirMAP -0.54 0 NA -0.37 type:-3.68, stage:-0.04, histology:-0.01, PAM50:0.03, ER:-0.31, PR:-0.11, HER2:0.07, Triple_Negative:-0.95
11 hsa-miR-92a-3p WNT5A 1.23 0.30313 -0.49 0.23864 miRNAWalker2 validate -0.46 0 NA -0.37 type:2.07, stage:-0.21, histology:-0.11, PAM50:-0.09, ER:0, PR:0.73, HER2:0.4, Triple_Negative:0.41
12 hsa-miR-30c-5p WNT7B 0.29 0.7388 -0.96 0.01632 miRNATAP -0.46 0 NA -0.37 type:0.5, stage:0.09, histology:-0.12, PAM50:0.23, ER:-0.16, PR:-0.38, HER2:0.51, Triple_Negative:-0.87
13 hsa-miR-96-5p SFRP1 0.1 0.81662 3.81 0 mirMAP -0.84 0 NA -0.36 type:-5.51, stage:-0.13, histology:-0.1, PAM50:-1.1, ER:0.29, PR:-0.23, HER2:-1.11, Triple_Negative:1.38
14 hsa-miR-589-5p CXXC4 0.23 0.66837 -1.31 0 MirTarget; miRNATAP -0.4 0 NA -0.35 type:-0.45, stage:-0.16, histology:-0.05, PAM50:0.36, ER:0.35, PR:-0.67, HER2:0.29, Triple_Negative:-0.74
15 hsa-miR-16-1-3p SFRP1 0.42 0.04437 3.81 0 MirTarget -0.71 0 NA -0.35 type:-5.14, stage:-0.13, histology:-0.1, PAM50:-1.13, ER:0.51, PR:-0.19, HER2:-1.02, Triple_Negative:1.71
16 hsa-miR-362-5p CAMK2B 0.82 0.01076 -1.56 0 miRNATAP -0.37 0 NA -0.34 type:2.37, stage:0.09, histology:0.04, PAM50:0.48, ER:0.51, PR:0.38, HER2:-0.17, Triple_Negative:0.47
17 hsa-miR-330-5p WIF1 0.56 0.19479 2.05 3.0E-5 miRanda -0.66 0 NA -0.34 type:-3.56, stage:-0.36, histology:-0.14, PAM50:-0.49, ER:0.1, PR:0.15, HER2:-0.11, Triple_Negative:1.58
18 hsa-miR-141-3p FZD4 0.52 0.54365 -0.76 0.18617 TargetScan -0.49 0 NA -0.33 type:-3.26, stage:-0.07, histology:-0.01, PAM50:0.04, ER:-0.28, PR:-0.14, HER2:0.08, Triple_Negative:-0.91
19 hsa-miR-7-1-3p SFRP1 -0.14 0.72688 3.81 0 MirTarget; mirMAP -0.63 0 NA -0.31 type:-6.3, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.41, PR:-0.25, HER2:-1.13, Triple_Negative:1.41
20 hsa-miR-374a-5p WNT3 0.47 0.30955 -0.24 0.21582 MirTarget -0.45 0 NA -0.31 type:2.78, stage:-0.04, histology:0.03, PAM50:0.32, ER:0.64, PR:-0.13, HER2:-0.56, Triple_Negative:0.95
21 hsa-miR-98-5p FZD10 0.61 0.24397 -0.3 0.16314 miRNAWalker2 validate -0.46 0 NA -0.3 type:0.29, stage:-0.15, histology:0.06, PAM50:-0.11, ER:0.43, PR:-0.08, HER2:-0.2, Triple_Negative:-0.03
22 hsa-miR-200b-3p FZD4 0.22 0.78639 -0.76 0.18617 mirMAP -0.44 0 NA -0.3 type:-3.23, stage:-0.08, histology:-0.02, PAM50:0.01, ER:0.06, PR:-0.15, HER2:0.02, Triple_Negative:-0.78
23 hsa-miR-30d-5p CAMK2A 0.17 0.88286 -0.12 0.63413 mirMAP -0.5 0 NA -0.29 type:1.39, stage:-0.09, histology:-0.14, PAM50:-0.14, ER:0.42, PR:-0.05, HER2:0.52, Triple_Negative:0
24 hsa-miR-141-5p DAAM2 0.15 0.85459 -0.04 0.92488 mirMAP -0.39 0 NA -0.29 type:-0.82, stage:0, histology:0.11, PAM50:-0.11, ER:0.4, PR:-0.19, HER2:-0.11, Triple_Negative:-0.02
25 hsa-miR-330-5p FZD4 0.56 0.19479 -0.76 0.18617 miRanda; miRNATAP -0.41 0 NA -0.28 type:-3.62, stage:-0.05, histology:-0.03, PAM50:0.01, ER:-0.2, PR:-0.04, HER2:0.17, Triple_Negative:-0.78
26 hsa-miR-29c-3p PRKX -0.64 0.52285 1.92 3.0E-5 mirMAP -0.39 0 NA -0.28 type:-0.81, stage:-0.07, histology:-0.09, PAM50:-0.28, ER:-0.22, PR:-0.2, HER2:-0.22, Triple_Negative:0.74
27 hsa-miR-93-5p CCND2 0.94 0.3985 -0.07 0.88928 miRNATAP -0.4 0 NA -0.27 type:-1.71, stage:-0.02, histology:-0.1, PAM50:-0.08, ER:-0.12, PR:0.12, HER2:-0.02, Triple_Negative:-0.02
28 hsa-miR-660-5p CXXC4 0.79 0.10863 -1.31 0 miRNATAP -0.56 0 NA -0.27 type:-0.88, stage:-0.14, histology:-0.07, PAM50:0.32, ER:0.43, PR:-0.69, HER2:0.13, Triple_Negative:-0.68
29 hsa-miR-361-5p PRICKLE2 0.3 0.67981 -1.2 0.01176 MirTarget; PITA; miRanda; miRNATAP -0.42 0 NA -0.27 type:-1.45, stage:-0.06, histology:-0.03, PAM50:0.06, ER:0.28, PR:0.18, HER2:0.17, Triple_Negative:-0.61
30 hsa-miR-29b-2-5p PRKCA -1.15 0.02347 1.09 0.00099 mirMAP -0.37 0 NA -0.27 type:-2.76, stage:-0.04, histology:-0.05, PAM50:-0.2, ER:-0.02, PR:-0.23, HER2:-0.2, Triple_Negative:0.06
31 hsa-miR-141-3p SOX17 0.52 0.54365 -0.56 0.03082 TargetScan -0.43 0 22921431 Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer; MicroRNA 141 was also found to down-regulate SOX17 expression and activate the WNT signal pathway -0.27 type:-1.81, stage:-0.08, histology:0.04, PAM50:0.02, ER:0.02, PR:-0.01, HER2:-0.05, Triple_Negative:-0.32
32 hsa-miR-532-5p CXXC4 0.84 0.32413 -1.31 0 MirTarget; PITA; miRNATAP -0.5 0 NA -0.26 type:-0.91, stage:-0.15, histology:-0.07, PAM50:0.33, ER:0.4, PR:-0.7, HER2:0.15, Triple_Negative:-0.69
33 hsa-miR-182-5p SFRP1 -0.35 0.79413 3.81 0 mirMAP -0.97 0 NA -0.26 type:-5.71, stage:-0.14, histology:-0.11, PAM50:-1.11, ER:0.42, PR:-0.17, HER2:-1.08, Triple_Negative:1.42
34 hsa-miR-2355-5p CAMK2B 0.52 0.30108 -1.56 0 mirMAP -0.53 0 NA -0.25 type:2.82, stage:0.06, histology:0.06, PAM50:0.48, ER:0.63, PR:0.36, HER2:-0.11, Triple_Negative:0.44
35 hsa-miR-342-3p FOSL1 -0.72 0.32809 2.26 0 miRanda -0.4 0 NA -0.25 type:-0.72, stage:-0.06, histology:-0.05, PAM50:-0.31, ER:-0.41, PR:-0.07, HER2:-0.34, Triple_Negative:0.94
36 hsa-miR-429 FZD4 0.45 0.43718 -0.76 0.18617 mirMAP -0.42 0 NA -0.25 type:-3.21, stage:-0.07, histology:-0.02, PAM50:0, ER:0.02, PR:-0.17, HER2:0.06, Triple_Negative:-0.8
37 hsa-miR-26a-5p VANGL1 -0.05 0.95817 0.09 0.85194 mirMAP -0.38 0 NA -0.25 type:1.19, stage:0.01, histology:0.01, PAM50:0.04, ER:-0.26, PR:0.09, HER2:0.17, Triple_Negative:0.03
38 hsa-miR-182-5p DAAM2 -0.35 0.79413 -0.04 0.92488 mirMAP -0.43 0 NA -0.24 type:-1.67, stage:0.02, histology:0.1, PAM50:-0.15, ER:0.32, PR:-0.11, HER2:-0.17, Triple_Negative:-0.26
39 hsa-miR-374a-5p CCND1 0.47 0.30955 -1.64 0.03536 MirTarget -0.56 0 27191497 microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression -0.23 type:2.74, stage:0.02, histology:0.03, PAM50:0.27, ER:1.01, PR:-0.19, HER2:0.22, Triple_Negative:-0.07
40 hsa-miR-664a-3p WNT10A -0.25 0.59988 2.09 0 mirMAP -0.42 0 NA -0.23 type:-1.33, stage:0.07, histology:-0.16, PAM50:-0.41, ER:-0.25, PR:0.09, HER2:-0.37, Triple_Negative:0.87
41 hsa-miR-3127-5p FZD4 0.15 0.56685 -0.76 0.18617 MirTarget -0.35 0 NA -0.22 type:-4.2, stage:-0.04, histology:-0.03, PAM50:0.04, ER:-0.24, PR:-0.14, HER2:0.15, Triple_Negative:-0.98
42 hsa-miR-30d-5p WNT5A 0.17 0.88286 -0.49 0.23864 mirMAP -0.4 0 NA -0.22 type:1.88, stage:-0.21, histology:-0.12, PAM50:-0.05, ER:0.1, PR:0.76, HER2:0.37, Triple_Negative:0.19
43 hsa-miR-17-5p FZD4 1.81 0.01774 -0.76 0.18617 TargetScan -0.38 0 NA -0.21 type:-4.29, stage:-0.04, histology:-0.03, PAM50:-0.03, ER:-0.33, PR:-0.09, HER2:0.09, Triple_Negative:-0.83
44 hsa-miR-21-5p FZD4 -0.14 0.92885 -0.76 0.18617 mirMAP -0.62 0 NA -0.21 type:-3.77, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.16, PR:-0.04, HER2:0.2, Triple_Negative:-1
45 hsa-let-7i-5p NLK 0.49 0.5398 -0.5 0.25036 miRNATAP -0.41 0 NA -0.21 type:1.13, stage:0.01, histology:0, PAM50:0.13, ER:-0.06, PR:0.02, HER2:0.3, Triple_Negative:-0.11
46 hsa-miR-183-5p PRKCA 0.2 0.86335 1.09 0.00099 miRNATAP -0.38 0 NA -0.21 type:-2.18, stage:-0.04, histology:-0.06, PAM50:-0.29, ER:-0.09, PR:-0.25, HER2:-0.12, Triple_Negative:0.17
47 hsa-miR-106b-5p FZD4 1.05 0.13909 -0.76 0.18617 miRNATAP -0.58 0 NA -0.2 type:-4.18, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.26, PR:-0.08, HER2:0.09, Triple_Negative:-0.9
48 hsa-miR-590-3p PRICKLE2 1.01 0 -1.2 0.01176 MirTarget; PITA; miRanda; mirMAP; miRNATAP -0.43 0 NA -0.2 type:-1.18, stage:-0.07, histology:-0.02, PAM50:0.05, ER:0.14, PR:0.17, HER2:0.23, Triple_Negative:-0.63
49 hsa-miR-200c-3p PRKCA 0.37 0.75644 1.09 0.00099 miRNATAP -0.38 0 NA -0.2 type:-2.33, stage:-0.03, histology:-0.06, PAM50:-0.28, ER:-0.07, PR:-0.24, HER2:-0.17, Triple_Negative:0.23
50 hsa-miR-625-5p SFRP1 -0.13 0.46001 3.81 0 MirTarget -0.63 0 NA -0.2 type:-5.05, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.61, PR:-0.14, HER2:-0.94, Triple_Negative:1.75
51 hsa-miR-148b-3p TCF7L2 0.14 0.82572 0.81 0.09031 miRNAWalker2 validate -0.36 0 NA -0.2 type:-1.45, stage:-0.06, histology:-0.05, PAM50:-0.28, ER:0.04, PR:-0.03, HER2:-0.02, Triple_Negative:0.23
52 hsa-miR-186-5p CCND1 1.04 0.14871 -1.64 0.03536 mirMAP -0.49 0 NA -0.19 type:2.53, stage:0.02, histology:0.04, PAM50:0.26, ER:0.88, PR:-0.16, HER2:0.16, Triple_Negative:-0.1
53 hsa-miR-374b-5p CCND1 0.48 0.36577 -1.64 0.03536 miRNAWalker2 validate; MirTarget -0.53 0 NA -0.19 type:2.66, stage:0.02, histology:0.03, PAM50:0.27, ER:1, PR:-0.17, HER2:0.2, Triple_Negative:-0.1
54 hsa-let-7a-3p FZD4 0.31 0.49951 -0.76 0.18617 mirMAP -0.41 0 NA -0.19 type:-3.99, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.14, PR:-0.05, HER2:0.1, Triple_Negative:-0.89
55 hsa-miR-18a-5p PRICKLE2 2.3 0 -1.2 0.01176 MirTarget -0.39 0 NA -0.19 type:-1.1, stage:-0.06, histology:-0.02, PAM50:0.04, ER:0.13, PR:0.11, HER2:0.24, Triple_Negative:-0.46
56 hsa-miR-19a-3p PRICKLE2 1.47 0.00036 -1.2 0.01176 MirTarget; miRNATAP -0.4 0 NA -0.19 type:-1.25, stage:-0.06, histology:-0.02, PAM50:0.06, ER:0.15, PR:0.13, HER2:0.22, Triple_Negative:-0.57
57 hsa-miR-19b-3p PRICKLE2 1.16 0.06285 -1.2 0.01176 MirTarget; miRNATAP -0.4 0 NA -0.19 type:-1.31, stage:-0.07, histology:-0.01, PAM50:0.06, ER:0.17, PR:0.18, HER2:0.18, Triple_Negative:-0.57
58 hsa-miR-590-5p PRICKLE2 1.4 0 -1.2 0.01176 MirTarget; PITA; miRanda -0.4 0 NA -0.19 type:-1.55, stage:-0.06, histology:-0.02, PAM50:0.05, ER:0.05, PR:0.15, HER2:0.19, Triple_Negative:-0.68
59 hsa-miR-15a-5p CCND2 0.34 0.60504 -0.07 0.88928 miRNAWalker2 validate; miRTarBase; miRNATAP -0.38 0 NA -0.18 type:-1.47, stage:-0.04, histology:-0.09, PAM50:-0.06, ER:-0.01, PR:0.18, HER2:0, Triple_Negative:-0.01
60 hsa-miR-192-5p FZD4 0.47 0.53116 -0.76 0.18617 miRNAWalker2 validate; mirMAP -0.42 0 NA -0.18 type:-4.21, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.25, PR:-0.09, HER2:0.12, Triple_Negative:-1
61 hsa-miR-93-5p PLCB1 0.94 0.3985 -0.07 0.85874 miRNATAP -0.38 0 NA -0.18 type:-3.61, stage:0.12, histology:-0.04, PAM50:-0.17, ER:-0.46, PR:-0.04, HER2:0.18, Triple_Negative:-0.68
62 hsa-miR-330-5p SOX17 0.56 0.19479 -0.56 0.03082 miRanda -0.46 0 NA -0.18 type:-2.24, stage:-0.06, histology:0.02, PAM50:-0.01, ER:0.09, PR:0.08, HER2:0.01, Triple_Negative:-0.26
63 hsa-miR-429 MAPK10 0.45 0.43718 -0.14 0.64996 miRNATAP -0.37 0 NA -0.17 type:-0.26, stage:-0.3, histology:-0.11, PAM50:-0.01, ER:0.31, PR:0, HER2:0.38, Triple_Negative:0.29
64 hsa-miR-185-5p NFATC2 0.41 0.43546 -0.4 0.13655 MirTarget -0.48 0 NA -0.17 type:-2.44, stage:-0.02, histology:-0.07, PAM50:-0.09, ER:0.25, PR:0.11, HER2:-0.35, Triple_Negative:-0.34
65 hsa-miR-107 PLCB1 0.35 0.52382 -0.07 0.85874 PITA; miRanda; miRNATAP -0.44 0 NA -0.16 type:-3.37, stage:0.1, histology:-0.04, PAM50:-0.14, ER:-0.38, PR:-0.02, HER2:0.2, Triple_Negative:-0.64
66 hsa-miR-98-5p FZD4 0.61 0.24397 -0.76 0.18617 MirTarget -0.53 0 NA -0.15 type:-4.23, stage:-0.03, histology:-0.03, PAM50:-0.02, ER:-0.19, PR:-0.03, HER2:0.11, Triple_Negative:-0.93
67 hsa-miR-148b-3p PRICKLE2 0.14 0.82572 -1.2 0.01176 MirTarget; miRNATAP -0.37 0 NA -0.15 type:-1.19, stage:-0.08, histology:-0.01, PAM50:0.09, ER:0.2, PR:0.17, HER2:0.22, Triple_Negative:-0.69
68 hsa-miR-15b-3p PRICKLE2 1.34 0.00123 -1.2 0.01176 mirMAP -0.35 0 NA -0.15 type:-1.02, stage:-0.07, histology:-0.02, PAM50:0.08, ER:0.18, PR:0.16, HER2:0.23, Triple_Negative:-0.55
69 hsa-miR-130b-3p FZD4 1.17 7.0E-5 -0.76 0.18617 mirMAP -0.41 0 NA -0.14 type:-4.01, stage:-0.05, histology:-0.03, PAM50:0, ER:-0.26, PR:-0.06, HER2:0.15, Triple_Negative:-0.89
70 hsa-miR-590-3p FZD4 1.01 0 -0.76 0.18617 miRanda; mirMAP; miRNATAP -0.41 0 NA -0.14 type:-4.19, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.25, PR:-0.05, HER2:0.12, Triple_Negative:-0.95
71 hsa-miR-106b-5p PLCB1 1.05 0.13909 -0.07 0.85874 miRNATAP -0.35 0 NA -0.14 type:-3.44, stage:0.1, histology:-0.04, PAM50:-0.16, ER:-0.42, PR:-0.04, HER2:0.18, Triple_Negative:-0.65
72 hsa-miR-361-5p MAPK8 0.3 0.67981 0.14 0.68637 PITA; miRanda; mirMAP -0.36 0 NA -0.13 type:-0.52, stage:-0.02, histology:-0.01, PAM50:0, ER:0.04, PR:-0.19, HER2:-0.17, Triple_Negative:-0.01
73 hsa-miR-429 SFRP1 0.45 0.43718 3.81 0 miRNATAP -0.48 0 NA -0.13 type:-5.59, stage:-0.14, histology:-0.12, PAM50:-1.12, ER:0.57, PR:-0.24, HER2:-1.09, Triple_Negative:1.63
74 hsa-let-7d-5p FZD4 0.74 0.278 -0.76 0.18617 MirTarget; miRNATAP -0.38 0 NA -0.11 type:-4.26, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.2, PR:-0.03, HER2:0.1, Triple_Negative:-0.94
75 hsa-miR-32-5p FZD4 0.53 0.1955 -0.76 0.18617 mirMAP -0.39 0 NA -0.1 type:-4.17, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.22, PR:-0.04, HER2:0.11, Triple_Negative:-0.96
76 hsa-miR-590-5p SOX17 1.4 0 -0.56 0.03082 miRanda -0.39 0 NA -0.1 type:-2.84, stage:-0.05, histology:0.02, PAM50:-0.03, ER:-0.02, PR:0.06, HER2:-0.04, Triple_Negative:-0.39
77 hsa-miR-429 WIF1 0.45 0.43718 2.05 3.0E-5 miRanda -0.58 0 NA -0.1 type:-4.24, stage:-0.35, histology:-0.13, PAM50:-0.56, ER:0.23, PR:0.15, HER2:-0.23, Triple_Negative:1.36
78 hsa-miR-361-5p PPP2R5E 0.3 0.67981 -0.11 0.80826 miRanda -0.36 0 NA -0.09 type:0.13, stage:0.04, histology:0.01, PAM50:0, ER:-0.14, PR:0, HER2:0.19, Triple_Negative:-0.18
79 hsa-miR-589-5p PRICKLE2 0.23 0.66837 -1.2 0.01176 MirTarget; miRNATAP -0.41 0 NA -0.09 type:-1.33, stage:-0.07, histology:-0.01, PAM50:0.07, ER:0.19, PR:0.21, HER2:0.25, Triple_Negative:-0.69
80 hsa-miR-340-5p ROCK2 0.36 0.35065 0.38 0.43385 mirMAP -0.4 0 NA -0.09 type:-2.16, stage:0, histology:0, PAM50:-0.09, ER:-0.14, PR:-0.31, HER2:-0.06, Triple_Negative:-0.23
81 hsa-miR-590-3p SOX17 1.01 0 -0.56 0.03082 miRanda; miRNATAP -0.44 0 NA -0.09 type:-2.62, stage:-0.05, histology:0.02, PAM50:-0.02, ER:0.05, PR:0.07, HER2:-0.02, Triple_Negative:-0.37
82 hsa-let-7i-5p CCND1 0.49 0.5398 -1.64 0.03536 miRNATAP -0.76 0 NA -0.08 type:2.76, stage:0.02, histology:0.04, PAM50:0.27, ER:1, PR:-0.14, HER2:0.19, Triple_Negative:-0.12
83 hsa-miR-92a-3p CCND1 1.23 0.30313 -1.64 0.03536 miRNAWalker2 validate -0.36 0 NA -0.08 type:2.79, stage:0.02, histology:0.05, PAM50:0.27, ER:0.98, PR:-0.15, HER2:0.18, Triple_Negative:-0.08
84 hsa-miR-146b-5p CXXC4 0.88 0.28494 -1.31 0 MirTarget; miRNATAP -0.4 0 NA -0.08 type:-0.44, stage:-0.15, histology:-0.06, PAM50:0.36, ER:0.52, PR:-0.66, HER2:0.18, Triple_Negative:-0.65
85 hsa-miR-107 FZD4 0.35 0.52382 -0.76 0.18617 miRNATAP -0.46 0 NA -0.06 type:-4.3, stage:-0.05, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.02, HER2:0.11, Triple_Negative:-0.97
86 hsa-miR-340-5p NFATC2 0.36 0.35065 -0.4 0.13655 miRNATAP -0.38 0 NA -0.06 type:-1.88, stage:-0.03, histology:-0.06, PAM50:-0.07, ER:0.44, PR:0.06, HER2:-0.32, Triple_Negative:-0.21
87 hsa-miR-590-3p AXIN2 1.01 0 -1.13 0.00118 MirTarget; PITA; miRanda; miRNATAP -0.36 0 NA -0.04 type:1.11, stage:-0.07, histology:0.02, PAM50:0.27, ER:0.52, PR:0.26, HER2:-0.03, Triple_Negative:0.15
88 hsa-miR-342-3p WIF1 -0.72 0.32809 2.05 3.0E-5 miRanda -0.9 0 NA -0.04 type:-4.35, stage:-0.35, histology:-0.13, PAM50:-0.51, ER:0.11, PR:0.19, HER2:-0.19, Triple_Negative:1.33
89 hsa-miR-29a-3p CCND1 0.46 0.68374 -1.64 0.03536 mirMAP -0.36 0 NA -0.03 type:2.74, stage:0.02, histology:0.04, PAM50:0.27, ER:0.99, PR:-0.13, HER2:0.18, Triple_Negative:-0.13
90 hsa-miR-532-5p NFATC4 0.84 0.32413 -1.31 0.01393 mirMAP -0.35 0 NA 0 type:0.52, stage:-0.06, histology:-0.02, PAM50:0.29, ER:0.71, PR:-0.23, HER2:-0.13, Triple_Negative:-0.32
91 hsa-miR-15a-5p FZD4 0.34 0.60504 -0.76 0.18617 MirTarget -0.4 0 NA 0.03 type:-4.41, stage:-0.04, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.01, HER2:0.11, Triple_Negative:-1.01
92 hsa-miR-186-5p CAMK2B 1.04 0.14871 -1.56 0 miRNAWalker2 validate; miRNATAP -0.42 0 NA 0.09 type:3.24, stage:0.05, histology:0.07, PAM50:0.5, ER:0.75, PR:0.47, HER2:-0.15, Triple_Negative:0.46
NumGOOverlapSizeP ValueAdj. P Value
1 WNT SIGNALING PATHWAY 18 351 1.153e-24 5.365e-21
2 NON CANONICAL WNT SIGNALING PATHWAY 10 140 5.437e-15 1.265e-11
3 CANONICAL WNT SIGNALING PATHWAY 9 95 1.1e-14 1.706e-11
4 NEGATIVE REGULATION OF WNT SIGNALING PATHWAY 10 197 1.73e-13 2.013e-10
5 REGULATION OF WNT SIGNALING PATHWAY 11 310 4.37e-13 4.066e-10
6 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 15 1021 2.841e-12 2.203e-09
7 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 17 1672 1.837e-11 1.221e-08
8 WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY 6 39 2.108e-11 1.226e-08
9 REGULATION OF CELL DIFFERENTIATION 16 1492 4.535e-11 2.345e-08
10 POSITIVE REGULATION OF CELL DIFFERENTIATION 12 823 9.505e-10 4.423e-07
11 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 13 1142 3.087e-09 1.306e-06
12 PATTERN SPECIFICATION PROCESS 9 418 6.772e-09 2.626e-06
13 POSITIVE REGULATION OF MOLECULAR FUNCTION 15 1791 7.639e-09 2.734e-06
14 CELLULAR RESPONSE TO ORGANIC SUBSTANCE 15 1848 1.172e-08 3.896e-06
15 DORSAL VENTRAL AXIS SPECIFICATION 4 20 1.959e-08 6.078e-06
16 RESPONSE TO OXYGEN CONTAINING COMPOUND 13 1381 3.027e-08 8.802e-06
17 CELL FATE COMMITMENT 7 227 3.606e-08 9.871e-06
18 CELLULAR RESPONSE TO RETINOIC ACID 5 65 4.148e-08 1.072e-05
19 POSITIVE REGULATION OF GENE EXPRESSION 14 1733 4.905e-08 1.201e-05
20 REGULATION OF ORGAN MORPHOGENESIS 7 242 5.592e-08 1.301e-05
21 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 13 1492 7.565e-08 1.676e-05
22 POSITIVE REGULATION OF CATALYTIC ACTIVITY 13 1518 9.273e-08 1.961e-05
23 CARDIOVASCULAR SYSTEM DEVELOPMENT 10 788 1.25e-07 2.422e-05
24 CIRCULATORY SYSTEM DEVELOPMENT 10 788 1.25e-07 2.422e-05
25 CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND 10 799 1.422e-07 2.646e-05
26 CELLULAR RESPONSE TO ACID CHEMICAL 6 175 2.054e-07 3.677e-05
27 AXIS SPECIFICATION 5 90 2.15e-07 3.706e-05
28 CELLULAR RESPONSE TO LIPID 8 457 2.631e-07 4.372e-05
29 REGIONALIZATION 7 311 3.078e-07 4.938e-05
30 VASCULATURE DEVELOPMENT 8 469 3.204e-07 4.969e-05
31 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 12 1395 3.358e-07 5.041e-05
32 RESPONSE TO LIPID 10 888 3.781e-07 5.332e-05
33 REGULATION OF PROTEIN MODIFICATION PROCESS 13 1710 3.728e-07 5.332e-05
34 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 11 1152 4.37e-07 5.98e-05
35 POSITIVE REGULATION OF CELL CYCLE 7 332 4.781e-07 6.356e-05
36 REGULATION OF CELLULAR RESPONSE TO STRESS 9 691 4.967e-07 6.419e-05
37 RESPONSE TO RETINOIC ACID 5 107 5.11e-07 6.426e-05
38 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 337 5.286e-07 6.473e-05
39 REGULATION OF ESTABLISHMENT OF PLANAR POLARITY 5 110 5.865e-07 6.997e-05
40 EPITHELIUM DEVELOPMENT 10 945 6.696e-07 7.6e-05
41 PROTEIN PHOSPHORYLATION 10 944 6.632e-07 7.6e-05
42 REGULATION OF CELL CYCLE 10 949 6.96e-07 7.711e-05
43 TISSUE MORPHOGENESIS 8 533 8.425e-07 9.117e-05
44 POSITIVE REGULATION OF CELL COMMUNICATION 12 1532 9.196e-07 9.508e-05
45 REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY 7 365 9.027e-07 9.508e-05
46 MAMMARY GLAND EPITHELIUM DEVELOPMENT 4 53 1.144e-06 0.0001157
47 POSITIVE REGULATION OF RESPONSE TO STIMULUS 13 1929 1.489e-06 0.0001469
48 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 10 1036 1.547e-06 0.0001469
49 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 10 1036 1.547e-06 0.0001469
50 MORPHOGENESIS OF AN EPITHELIUM 7 400 1.662e-06 0.0001516
51 REGULATION OF PHOSPHORUS METABOLIC PROCESS 12 1618 1.645e-06 0.0001516
52 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 11 1360 2.258e-06 0.0002021
53 PEPTIDYL SERINE MODIFICATION 5 148 2.545e-06 0.0002235
54 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 10 1135 3.523e-06 0.0003035
55 REGULATION OF JNK CASCADE 5 159 3.618e-06 0.0003061
56 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 6 289 3.833e-06 0.0003185
57 NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY 5 162 3.965e-06 0.0003237
58 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 7 470 4.823e-06 0.000387
59 NEGATIVE REGULATION OF CELL COMMUNICATION 10 1192 5.457e-06 0.0004304
60 REGULATION OF JUN KINASE ACTIVITY 4 81 6.314e-06 0.0004897
61 RESPONSE TO ACID CHEMICAL 6 319 6.754e-06 0.0005152
62 RESPONSE TO KETONE 5 182 6.998e-06 0.000525
63 PHOSPHORYLATION 10 1228 7.109e-06 0.000525
64 STEM CELL DIFFERENTIATION 5 190 8.625e-06 0.0006271
65 INTRACELLULAR SIGNAL TRANSDUCTION 11 1572 9.186e-06 0.0006576
66 ANTERIOR POSTERIOR PATTERN SPECIFICATION 5 194 9.543e-06 0.0006728
67 DORSAL VENTRAL PATTERN FORMATION 4 91 1.004e-05 0.0006972
68 REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 5 197 1.028e-05 0.0007034
69 REGULATION OF CELL MORPHOGENESIS 7 552 1.377e-05 0.0009283
70 REGULATION OF HYDROLASE ACTIVITY 10 1327 1.408e-05 0.000936
71 BLOOD VESSEL MORPHOGENESIS 6 364 1.431e-05 0.000938
72 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 8 801 1.707e-05 0.001103
73 GLAND DEVELOPMENT 6 395 2.271e-05 0.001447
74 REGULATION OF CELL DEVELOPMENT 8 836 2.324e-05 0.001461
75 REGULATION OF CANONICAL WNT SIGNALING PATHWAY 5 236 2.456e-05 0.001502
76 POSITIVE REGULATION OF CELL DEATH 7 605 2.485e-05 0.001502
77 REGULATION OF EMBRYONIC DEVELOPMENT 4 114 2.447e-05 0.001502
78 SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION 6 404 2.577e-05 0.001527
79 NEGATIVE REGULATION OF CELL DIFFERENTIATION 7 609 2.593e-05 0.001527
80 REPRODUCTIVE SYSTEM DEVELOPMENT 6 408 2.724e-05 0.001546
81 NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 4 117 2.71e-05 0.001546
82 MAMMARY GLAND DEVELOPMENT 4 117 2.71e-05 0.001546
83 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 11 1805 3.396e-05 0.001881
84 REGULATION OF RESPONSE TO STRESS 10 1468 3.388e-05 0.001881
85 EMBRYO DEVELOPMENT 8 894 3.757e-05 0.002057
86 POSITIVE REGULATION OF HYDROLASE ACTIVITY 8 905 4.099e-05 0.002218
87 REGULATION OF MAPK CASCADE 7 660 4.332e-05 0.002317
88 PEPTIDYL THREONINE MODIFICATION 3 46 4.426e-05 0.00234
89 TISSUE DEVELOPMENT 10 1518 4.517e-05 0.002362
90 POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE 4 135 4.748e-05 0.002455
91 REGULATION OF GTPASE ACTIVITY 7 673 4.903e-05 0.002507
92 DIGESTIVE TRACT MORPHOGENESIS 3 48 5.033e-05 0.002545
93 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 8 957 6.092e-05 0.002991
94 POSITIVE REGULATION OF MAPK CASCADE 6 470 5.998e-05 0.002991
95 RESPONSE TO TRANSFORMING GROWTH FACTOR BETA 4 144 6.106e-05 0.002991
96 POSITIVE REGULATION OF KINASE ACTIVITY 6 482 6.896e-05 0.003342
97 RESPONSE TO CYTOKINE 7 714 7.125e-05 0.003418
98 RHYTHMIC PROCESS 5 298 7.455e-05 0.003524
99 UROGENITAL SYSTEM DEVELOPMENT 5 299 7.574e-05 0.003524
100 POSITIVE REGULATION OF WNT SIGNALING PATHWAY 4 152 7.535e-05 0.003524
101 POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 4 154 7.927e-05 0.003616
102 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 11 1977 7.884e-05 0.003616
103 GASTRULATION 4 155 8.128e-05 0.003637
104 REPRODUCTION 9 1297 8.13e-05 0.003637
105 VASCULOGENESIS 3 59 9.355e-05 0.004146
106 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 4 162 9.645e-05 0.004234
107 REGULATION OF MAP KINASE ACTIVITY 5 319 0.0001027 0.004468
108 SOMITOGENESIS 3 62 0.0001085 0.00465
109 TUBE MORPHOGENESIS 5 323 0.0001089 0.00465
110 REGULATION OF PROTEIN BINDING 4 168 0.000111 0.004696
111 POSITIVE REGULATION OF JUN KINASE ACTIVITY 3 63 0.0001138 0.004771
112 NEGATIVE REGULATION OF CELL GROWTH 4 170 0.0001162 0.004785
113 REGULATION OF CELLULAR COMPONENT MOVEMENT 7 771 0.0001153 0.004785
114 POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY 2 11 0.0001186 0.004842
115 REGULATION OF KINASE ACTIVITY 7 776 0.00012 0.004857
116 POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION 3 67 0.0001367 0.005438
117 REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION 3 67 0.0001367 0.005438
118 REGULATION OF OSSIFICATION 4 178 0.0001387 0.00547
119 HEART FORMATION 2 12 0.0001422 0.005515
120 MAMMARY GLAND EPITHELIAL CELL PROLIFERATION 2 12 0.0001422 0.005515
121 TUBE DEVELOPMENT 6 552 0.0001452 0.005585
122 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 6 554 0.0001481 0.005603
123 NEUROGENESIS 9 1402 0.0001479 0.005603
124 REGULATION OF CELL CYCLE PROCESS 6 558 0.000154 0.00578
125 PROTEIN AUTOPHOSPHORYLATION 4 192 0.0001855 0.006852
126 RESPONSE TO ALCOHOL 5 362 0.0001855 0.006852
127 REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE 2 14 0.0001957 0.006952
128 POSITIVE REGULATION OF MEIOTIC CELL CYCLE 2 14 0.0001957 0.006952
129 CELL MIGRATION INVOLVED IN GASTRULATION 2 14 0.0001957 0.006952
130 CONVERGENT EXTENSION 2 14 0.0001957 0.006952
131 REGULATION OF SYNAPSE MATURATION 2 14 0.0001957 0.006952
132 ORGAN MORPHOGENESIS 7 841 0.0001976 0.006964
133 REGULATION OF CELL DEATH 9 1472 0.0002142 0.007457
134 SOMITE DEVELOPMENT 3 78 0.0002148 0.007457
135 DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION 6 602 0.0002325 0.008012
136 REGULATION OF CELL PROLIFERATION 9 1496 0.000242 0.00828
137 JNK CASCADE 3 82 0.000249 0.008377
138 POSITIVE REGULATION OF MAP KINASE ACTIVITY 4 207 0.0002474 0.008377
139 NEURON DIFFERENTIATION 7 874 0.0002502 0.008377
140 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 7 876 0.0002538 0.008434
141 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 6 616 0.0002631 0.008683
142 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 9 1517 0.0002688 0.008745
143 NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH 3 84 0.0002673 0.008745
144 DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS 4 216 0.0002909 0.009399
145 REGULATION OF CELL ADHESION 6 629 0.0002944 0.009447
NumGOOverlapSizeP ValueAdj. P Value
1 FRIZZLED BINDING 5 36 1.952e-09 1.813e-06
2 WNT PROTEIN BINDING 4 31 1.258e-07 5.843e-05
3 PROTEIN KINASE ACTIVITY 9 640 2.606e-07 6.053e-05
4 PROTEIN SERINE THREONINE KINASE ACTIVITY 8 445 2.148e-07 6.053e-05
5 MAP KINASE ACTIVITY 3 14 1.096e-06 0.0002037
6 KINASE ACTIVITY 9 842 2.564e-06 0.000397
7 ENZYME BINDING 12 1737 3.476e-06 0.0004613
8 WNT ACTIVATED RECEPTOR ACTIVITY 3 22 4.601e-06 0.0005342
9 TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS 9 992 9.748e-06 0.001006
10 PROTEIN DOMAIN SPECIFIC BINDING 7 624 3.03e-05 0.002815
11 G PROTEIN COUPLED RECEPTOR BINDING 5 259 3.831e-05 0.003236
12 MOLECULAR FUNCTION REGULATOR 9 1353 0.0001126 0.00805
13 TRANSCRIPTION FACTOR BINDING 6 524 0.0001092 0.00805
NumGOOverlapSizeP ValueAdj. P Value
1 ENDOCYTIC VESICLE MEMBRANE 6 152 8.914e-08 5.206e-05
2 ENDOCYTIC VESICLE 6 256 1.903e-06 0.0005558

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04310_Wnt_signaling_pathway 30 151 1.014e-65 1.826e-63
2 hsa04916_Melanogenesis 12 101 1.123e-20 1.011e-18
3 hsa04390_Hippo_signaling_pathway 10 154 1.435e-14 8.613e-13
4 hsa04912_GnRH_signaling_pathway 7 101 1.255e-10 5.649e-09
5 hsa04340_Hedgehog_signaling_pathway 5 56 1.937e-08 6.972e-07
6 hsa04720_Long.term_potentiation 5 70 6.047e-08 1.814e-06
7 hsa04971_Gastric_acid_secretion 5 74 8.015e-08 2.061e-06
8 hsa04010_MAPK_signaling_pathway 7 268 1.122e-07 2.525e-06
9 hsa04012_ErbB_signaling_pathway 5 87 1.814e-07 3.627e-06
10 hsa04510_Focal_adhesion 6 200 4.51e-07 8.118e-06
11 hsa04020_Calcium_signaling_pathway 5 177 6.11e-06 9.999e-05
12 hsa04114_Oocyte_meiosis 4 114 2.447e-05 0.0003628
13 hsa04270_Vascular_smooth_muscle_contraction 4 116 2.62e-05 0.0003628
14 hsa04722_Neurotrophin_signaling_pathway 4 127 3.739e-05 0.0004627
15 hsa04380_Osteoclast_differentiation 4 128 3.856e-05 0.0004627
16 hsa04370_VEGF_signaling_pathway 3 76 0.0001988 0.002237
17 hsa04664_Fc_epsilon_RI_signaling_pathway 3 79 0.000223 0.002361
18 hsa04914_Progesterone.mediated_oocyte_maturation 3 87 0.0002965 0.002949
19 hsa04970_Salivary_secretion 3 89 0.000317 0.002949
20 hsa04540_Gap_junction 3 90 0.0003276 0.002949
21 hsa04360_Axon_guidance 3 130 0.0009582 0.008213
22 hsa04650_Natural_killer_cell_mediated_cytotoxicity 3 136 0.001092 0.00891
23 hsa04910_Insulin_signaling_pathway 3 138 0.001139 0.00891
24 hsa04151_PI3K_AKT_signaling_pathway 4 351 0.001782 0.01336
25 hsa04062_Chemokine_signaling_pathway 3 189 0.002795 0.02012
26 hsa04621_NOD.like_receptor_signaling_pathway 2 59 0.003529 0.02443
27 hsa04920_Adipocytokine_signaling_pathway 2 68 0.004659 0.0301
28 hsa04115_p53_signaling_pathway 2 69 0.004794 0.0301
29 hsa04730_Long.term_depression 2 70 0.004931 0.0301
30 hsa04622_RIG.I.like_receptor_signaling_pathway 2 71 0.005069 0.0301
31 hsa04014_Ras_signaling_pathway 3 236 0.005206 0.0301
32 hsa04520_Adherens_junction 2 73 0.00535 0.0301
33 hsa04662_B_cell_receptor_signaling_pathway 2 75 0.005639 0.03076
34 hsa04070_Phosphatidylinositol_signaling_system 2 78 0.006086 0.03222
35 hsa04972_Pancreatic_secretion 2 101 0.01002 0.05104
36 hsa04620_Toll.like_receptor_signaling_pathway 2 102 0.01021 0.05104
37 hsa04660_T_cell_receptor_signaling_pathway 2 108 0.01139 0.0554
38 hsa04670_Leukocyte_transendothelial_migration 2 117 0.01326 0.06283
39 hsa04110_Cell_cycle 2 128 0.01573 0.07258
40 hsa04740_Olfactory_transduction 3 388 0.01996 0.08983
41 hsa04630_Jak.STAT_signaling_pathway 2 155 0.02252 0.09888
42 hsa04141_Protein_processing_in_endoplasmic_reticulum 2 168 0.02616 0.1121

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1 RP11-736K20.5 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p 10 FZD4 Sponge network -1.12 0 -0.757 0.18617 0.911
2 RP11-175K6.1 hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-98-5p 10 FZD4 Sponge network -0.575 0.00197 -0.757 0.18617 0.797
3 RP11-1101K5.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p 12 FZD4 Sponge network -0.926 0.2253 -0.757 0.18617 0.645
4 TRHDE-AS1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p 19 FZD4 Sponge network -1.208 0.04058 -0.757 0.18617 0.639
5 ADIPOQ-AS1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p 15 FZD4 Sponge network -0.771 0.3685 -0.757 0.18617 0.618
6 ADAMTS9-AS2 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-590-3p;hsa-miR-98-5p 16 FZD4 Sponge network -0.668 0.037 -0.757 0.18617 0.617
7 MIR143HG hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p 18 FZD4 Sponge network -0.86 0.00094 -0.757 0.18617 0.604
8 EMX2OS hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-590-3p 16 FZD4 Sponge network -0.677 0.02209 -0.757 0.18617 0.585
9 AL035610.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p 16 FZD4 Sponge network -1.553 0.00698 -0.757 0.18617 0.581
10 ADAMTS9-AS1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p 18 FZD4 Sponge network -0.962 0.04922 -0.757 0.18617 0.572
11 ALDH1L1-AS2 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p 13 FZD4 Sponge network 0.289 0.67904 -0.757 0.18617 0.564
12 RP11-384P7.7 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p 14 FZD4 Sponge network -1.959 2.0E-5 -0.757 0.18617 0.558
13 MEG3 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-98-5p 10 FZD4 Sponge network -0.963 0 -0.757 0.18617 0.539
14 PGM5-AS1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p 10 FZD4 Sponge network -2.259 0.00169 -0.757 0.18617 0.53
15 LINC00968 hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p 11 FZD4 Sponge network 0.742 0.04551 -0.757 0.18617 0.52
16 AGAP11 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p 12 FZD4 Sponge network -1.402 0 -0.757 0.18617 0.513
17 RP11-92A5.2 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p 12 FZD4 Sponge network -1.261 0.13256 -0.757 0.18617 0.487
18 AC108142.1 hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p 10 FZD4 Sponge network -0.622 0.11008 -0.757 0.18617 0.482
19 RP11-180N14.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-21-5p;hsa-miR-98-5p 10 FZD4 Sponge network -1.548 0 -0.757 0.18617 0.481
20 DIO3OS hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-98-5p 13 FZD4 Sponge network -1.023 0.0019 -0.757 0.18617 0.471
21 AC003991.3 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-590-3p 13 FZD4 Sponge network -0.951 0.00515 -0.757 0.18617 0.465
22 AC004947.2 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-590-3p 15 FZD4 Sponge network -2.525 0 -0.757 0.18617 0.437
23 RP11-116O18.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-98-5p 13 FZD4 Sponge network -2.5 0 -0.757 0.18617 0.431
24 RP11-276H19.1 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-98-5p 10 FZD4 Sponge network 0.128 0.62793 -0.757 0.18617 0.423
25 ACTA2-AS1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-590-3p 14 FZD4 Sponge network -0.715 0.01146 -0.757 0.18617 0.42
26 RP11-822E23.8 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-330-5p 13 FZD4 Sponge network -2.084 0 -0.757 0.18617 0.42
27 RP11-286B14.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-98-5p 12 FZD4 Sponge network 0.222 0.70649 -0.757 0.18617 0.375
28 LINC00648 hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p 14 FZD4 Sponge network -1.323 0.05538 -0.757 0.18617 0.375
29 AC141928.1 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-98-5p 11 FZD4 Sponge network -3.06 0 -0.757 0.18617 0.344
30 RP11-507B12.2 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-330-5p;hsa-miR-98-5p 13 FZD4 Sponge network -4.402 0 -0.757 0.18617 0.343
31 RP11-276H19.2 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-98-5p 10 FZD4 Sponge network 0.056 0.92103 -0.757 0.18617 0.339
32 RP11-978I15.10 hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429 11 FZD4 Sponge network -4.189 0 -0.757 0.18617 0.332
33 RP11-403B2.7 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-590-3p 10 FZD4 Sponge network -1.412 2.0E-5 -0.757 0.18617 0.317
34 LINC01085 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p 15 FZD4 Sponge network -2.762 0 -0.757 0.18617 0.298
35 CTB-107G13.1 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p 11 FZD4 Sponge network -4.202 0 -0.757 0.18617 0.291
36 CTD-3247F14.2 hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-98-5p 12 FZD4 Sponge network -1.581 0.00115 -0.757 0.18617 0.276
37 RP11-398E10.1 hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p;hsa-miR-98-5p 10 FZD4 Sponge network -1.149 0.16482 -0.757 0.18617 0.272
38 LDLRAD4-AS1 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-3127-5p;hsa-miR-590-3p 10 FZD4 Sponge network -4.332 0 -0.757 0.18617 0.258
39 RP11-32B5.7 hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p 11 FZD4 Sponge network -2.009 1.0E-5 -0.757 0.18617 0.255

Quest ID: 98c2be7cbf782d8d6e2f79d877a6f100